The Digital Trust Paradox: Despite Hailing Its Importance, For Most It’s Not a Priority
9.5.2023 07:00:00 EEST | Business Wire | Press release
New research by global digital trust association ISACA underscores the importance of digital trust for business and IT professionals in Europe. The study shows 94% of respondents believe that digital trust is relevant to their organisation, with 93% of IT professionals stating it is relevant for their current job. And its significance will only grow as 83% of businesses think digital trust will be even more important over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005811/en/
ISACA defines digital trust as the confidence in the integrity of the relationship, interactions and transactions among providers and consumers within an associated digital ecosystem. Its key components include security, data integrity, privacy, governance and assurance, and it is a driving factor in consumer decisions and enterprise resilience.
Organisations must prioritise cross-functional teams, communication channels, and training programs that encourage collaboration to achieve digital transformation objectives and maintain trust with stakeholders. But according to ISACA’s new research, less than half (44%) of respondents feel there is sufficient collaboration among professionals in their organisation who work in digital trust fields such as security, risk, governance, assurance, privacy, and quality.
Digital trust is key to success
Over three quarters (79%) of respondents recognise that organisations that demonstrate their commitment to digital trust will be more successful. They believe that businesses with high levels of digital trust are more likely to have a positive reputation (70%); experience fewer privacy breaches (57%); experience fewer cybersecurity incidents (55%) and have more reliable data on which to make decisions and have stronger customer loyalty (51%).
Despite respondents highlighting its importance, there is a clear disparity between thought and action when it comes to digital trust.
ISACA's research finds that only 7% of European business and IT professionals are completely confident in the digital trustworthiness of their organisation, with a staggering one in three (33%) not measuring their digital trust practises at all. Only a quarter (27%) of organisations provide any kind of digital trust training to staff, and 41% do not have a staff role dedicated to digital trust and are unlikely to in the next five years.
Chris Dimitriadis, Chief Global Strategy Officer at ISACA, said: “Businesses recognise the importance of digital trust, but most are struggling to achieve it. Employees aren’t getting the right training to build their skills in this area, and we need to change the record through a combined training and credentialing approach that crosses digital trust domains like cybersecurity, audit, risk, privacy and governance of technology among others. That way, businesses can understand the critical factors that drive organisational success and learn about the strategies and techniques needed to establish and maintain digital trust.”
Barriers to digital trust
There are several barriers to achieving digital trust. According to the research, 41% of respondents cite both a lack of leadership buy-in and a lack of alignment between digital trust and enterprise goals as blockers to progress. A similar number (38%) signal that a lack of budget was a barrier, indicating that businesses are struggling to find the resource and reason to improve the trustworthiness of their organisation.
Similar sentiments were found with regards to the provision of digital trust training. 49% of respondents identify a lack of staff skills and training as an obstacle to achieving high levels of digital trust. The findings indicate the need for businesses to prioritise investment in digital trust training and skills development – from the C-suite right down to entry level employees.
Dimitriadis continues : “To truly achieve digital trust, high levels of collaboration and a holistic approach are essential. From IT and engineering to HR and sales, all departments must now align on how digital trust can be achieved through a unified strategy and then take the steps to do so.
“The organisations that do keep digital trust front of mind will not only protect themselves against cyberattacks, but also protect their businesses’ bottom line by building long term customer loyalty – in turn increasing customer retention. Those that do not will see these things negatively impacted and their business success undermined.”
Rolf von Roessing, ISACA Evangelist, said: “Cyberattacks are on the rise and customers increasingly recognise their sophisticated nature. They’ll therefore expect businesses to take the necessary steps to protect and secure their personal data. Those who adopt a company-wide strategy to build digital trust will establish themselves as a credible authority among customer bases and sustainably reap the long-term rewards.”
Notes to editors
Methodology
All figures are based on fieldwork conducted by ISACA. Fieldwork was undertaken in 8,100 among global business and IT professionals, including 1354 within Europe.
About ISACA
For more than 50 years, ISACA (www.isaca.org) has equipped individuals and enterprises with the knowledge, credentials, education, training, and community to progress their careers, transform their organisations, and build a more trusted and ethical digital world. ISACA's member base in Europe exceeds 30,000, and the organization has further strengthened its presence in the region by establishing a new regional office in Dublin, Ireland, in 2022. Through its foundation One In Tech, ISACA supports IT education and career pathways for under resourced and underrepresented populations.
Learn More
For resources on digital trust, visit www.isaca.org/digital-trust. The State of Digital Trust report is available as a free download at www.isaca.org/state-of-digital-trust.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005811/en/
Contact information
firstlight group
ISACAteam@firstlightgroup.io 07526565507
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
